UVSQ laboratory receives European funding to research ultra-rare diseases

The European Commission has granted funding to UVSQ’s END-ICAP laboratory to pursue and improve its research into ultra-rare diseases, which affect a very small number of people. The team headed by Dr. Goyenvalle will be working to meet a number of challenges, from the transition of the laboratory’s antisense research to its clinical application, including dissemination, intellectual property protection and entrepreneurship. The aim of the program is to train the next generation of researchers by giving 12 doctoral researchers the skills and knowledge they need to advance research to clinical application. In this way, the program will help to keep Europe competitive within this rapidly developing field.